Evaluation of serum percent trisialotransferrin as potential predictive biomarker of hepatocellular dedifferentiation in chronic liver disease

Clinica Chimica Acta

Volumn 403, Issue 1-2, 2009, Pages 188-193

  Gressner, Olav A ^a   Jafari, Shadi ^a   Erkens, Manfred ^a   Gao, Chunfang ^b   Stanzel, Sven ^a   Gressner, Axel M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CDT; Hepatocellular carcinoma; Liver fibrosis; Trisialotransferrin

Indexed keywords

TRANSFERRIN; TRISIALOTRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FIBROGENESIS; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PRIORITY JOURNAL; TRANSFERRIN BLOOD LEVEL; VIRUS CARCINOGENESIS;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL DEDIFFERENTIATION; CHRONIC DISEASE; CONTINENTAL POPULATION GROUPS; FEMALE; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PROTEIN ISOFORMS; SIALOGLYCOPROTEINS; TRANSFERRIN;

HEPATITIS C VIRUS;

EID: 64849100308     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.02.017     Document Type: Article

References (37)

1. Rocken C., and Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 19 (2001) 269-278
2. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nature Rev 6 (2006) 674-687
3. Ueno Y., Moriyama M., Uchida T., and Arakawa Y. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 33 (2001) 357-362
4. Zeisberg M., Hanai J., Sugimoto H., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature Med 9 (2003) 964-968
5. Abreu J.G., Ketpura N.I., Reversade B., and De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4 (2002) 599-604
6. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172 (2006) 973-981
7. Kalluri R., and Zeisberg M. Fibroblasts in cancer. Nature Rev 6 (2006) 392-401
8. Zeisberg M., Yang C., Martino M., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282 (2007) 23,337-23,347
9. Kim Y.J., Lee H.S., Im J.P., et al. Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 35 (2003) 196-202
10. Arndt T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem 47 (2001) 13-27
11. Hannuksela M.L., Liisanantti M.K., Nissinen A.E., and Savolainen M.J. Biochemical markers of alcoholism. Clin Chem Lab Med 45 (2007) 953-961
12. Niemela O. Biomarkers in alcoholism. Clin Chim Acta 377 (2007) 39-49
13. Arndt T., van der Meijden B.B., and Wielders J.P. Atypical serum transferrin isoform distribution in liver cirrhosis studied by HPLC, capillary electrophoresis and transferrin genotyping. Clin Chim Acta 394 (2008) 42-46
14. Bean P., and Peter J.B. Allelic D variants of transferrin in evaluation of alcohol abuse: differential diagnosis by isoelectric focusing-immunoblotting-laser densitometry. Clin Chem 40 (1994) 2078-2083
15. Murawaki Y., Sugisaki H., Yuasa I., and Kawasaki H. Serum carbohydrate-deficient transferrin in patients with nonalcoholic liver disease and with hepatocellular carcinoma. Clin Chim Acta 259 (1997) 97-108
16. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
17. O'Brien C.P. The CAGE questionnaire for detection of alcoholism: a remarkably useful but simple tool. JAMA 300 (2008) 2054-2056
18. Kitchens J.M. Does this patient have an alcohol problem?. JAMA 272 (1994) 1782-1787
19. Bernadt M.W. Comparison of questionnaire and laboratory tests in the detection of excessive drinking and alcoholism. Lancet 6 (1982) 325-328
20. Jeppsson J.O., Arndt T., Schellenberg F., et al. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. Clin Chem Lab Med 45 (2007) 558-562
21. Zhou L., Rui J.A., Ye D.X., Wang S.B., Chen S.G., and Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg 32 (2008) 1748-1756
22. Lario S., Inigo P., Campistol J.M., Poch E., Rivera F., and Oppenheimer F. Restriction enzyme-based method for transforming growth factor-beta(1) genotyping: nonisotopic detection of polymorphisms in codons 10 and 25 and the 5′-flanking region. Clin Chem 45 (1999) 1290-1292
23. Kamboh M.I., and Ferrell R.E. Human transferrin polymorphism. Hum Hered 9 (1988) 411-417
24. Smithies O. Variations in serum ß-globulins. Nature 180 (1957) 1482-1483
25. Giblett E.R., Hickman C.G., and Smithies O. Serum transferrins. Nature 183 (1959) 1589-1590
26. Cavalli-Sforza L., Menozzi P., and Piazza A. The history and the geography of human genes (1994), Princeton University Press, Princeton, NJ 188pp
27. Heggli D.E., Aurebekk A., Granum B., Westby C., Lovli T., and Sundrehagen E. Should tri-sialo-transferrin be included when calculating carbohydrate-deficient transferrin for diagnosing elevated alcohol intake?. Alcohol Alcohol 31 (1996) 381-384
28. Lakshman M.R., Rao M.N., and Marmillot P. Alcohol and molecular regulation of protein glycosylation and function. Alcohol 19 (1999) 239-247
29. Niehues R., Hasilik M., Alton G., et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy [see comments]. J Clin Invest 101 (1998) 1414-1420
30. Marquardt T., Hasilik M., Niehues R., et al. Carbohydrate-deficient glycoprotein syndrome type Ib: phosphomannose isomerase deficiency. Eur J Pediatr 157 (1998) 174A
31. de Koning T.J., Dorland L., van Diggelen O.P., et al. A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency. Biochem Biophys Res Commun 245 (1998) 38-42
32. Jaeken J., Matthijs G., Saudubray J.M., et al. Phosphomannose isomerase deficiency: a carbohydrate-deficient glycoprotein syndrome with hepatic-intestinal presentation [letter]. Am J Hum Genet 62 (1998) 1535-1539
33. Gong M., Castillo L., Redman R.S., et al. Down-regulation of liver Galbeta1, 4GlcNAc alpha2, 6-sialyltransferase gene by ethanol significantly correlates with alcoholic steatosis in humans. Metabolism 57 (2008) 1663-1668
34. Gong M., Garige M., Hirsch K., and Lakshman M.R. Liver Galbeta1,4GlcNAc alpha2,6-sialyltransferase is down-regulated in human alcoholics: possible cause for the appearance of asialoconjugates. Metabolism 56 (2007) 1241-1247
35. Miyagi T., Koseki M., and Tsuiki S. Comparative study of the levels of sialyltransferases responsible for the formation of sugar chains in glycoproteins and gangliosides in rat liver and hepatomas. Jpn J Cancer Res 79 (1988) 742-749
36. Hagberg B.A., Blennow G., Kristiansson B., and Stibler H. Carbohydrate-deficient glycoprotein syndromes: peculiar groups of new disorders. Pediatr Neurol 9 (1993) 255-262
37. Jaeken J., van Eijk H.G., van der Heul C., Corbeel L., Eeckels R., and Eggermont E. Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome. Clin Chim Acta 144 (1984) 245-247